These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34900242)

  • 21.
    Medina-Barandica J; Contreras-Puentes N; Tarón-Dunoyer A; Durán-Lengua M; Alviz-Amador A
    Inform Med Unlocked; 2023; 40():101278. PubMed ID: 37305192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COVID-19 liver and gastroenterology findings: An
    Peiter GC; de Souza CBT; de Oliveira LM; Pagliarin LG; Dos Anjos VNF; da Silva FAF; de Melo FF; Teixeira KN
    World J Hepatol; 2022 Jun; 14(6):1131-1141. PubMed ID: 35978663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In Silico Analysis of Bacteriocins from Lactic Acid Bacteria Against SARS-CoV-2.
    Erol I; Kotil SE; Fidan O; Yetiman AE; Durdagi S; Ortakci F
    Probiotics Antimicrob Proteins; 2023 Feb; 15(1):17-29. PubMed ID: 34837166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phytoconstituents from ten natural herbs as potent inhibitors of main protease enzyme of SARS-COV-2:
    Kumar N; Singh A; Gulati HK; Bhagat K; Kaur K; Kaur J; Dudhal S; Duggal A; Gulati P; Singh H; Singh JV; Bedi PMS
    Phytomed Plus; 2021 Nov; 1(4):100083. PubMed ID: 35403086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction of Bioactive Compounds of Moringa oleifera Leaves with SARS-CoV-2 Proteins to Combat COVID-19 Pathogenesis: a Phytochemical and In Silico Analysis.
    Siddiqui S; Upadhyay S; Ahmad R; Barkat MA; Jamal A; Alothaim AS; Hassan MZ; Rahman MA; Arshad M; Ahamad T; Khan MF; Shankar H; Ali M; Kaleem S; Ahmad J
    Appl Biochem Biotechnol; 2022 Dec; 194(12):5918-5944. PubMed ID: 35838886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2.
    Prajapat M; Shekhar N; Sarma P; Avti P; Singh S; Kaur H; Bhattacharyya A; Kumar S; Sharma S; Prakash A; Medhi B
    J Mol Graph Model; 2020 Dec; 101():107716. PubMed ID: 32866780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy.
    Ridgway H; Chasapis CT; Kelaidonis K; Ligielli I; Moore GJ; Gadanec LK; Zulli A; Apostolopoulos V; Mavromoustakos T; Matsoukas JM
    Viruses; 2022 May; 14(5):. PubMed ID: 35632769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-Viral and Immunomodulatory Properties of Propolis: Chemical Diversity, Pharmacological Properties, Preclinical and Clinical Applications, and In Silico Potential against SARS-CoV-2.
    Yosri N; Abd El-Wahed AA; Ghonaim R; Khattab OM; Sabry A; Ibrahim MAA; Moustafa MF; Guo Z; Zou X; Algethami AFM; Masry SHD; AlAjmi MF; Afifi HS; Khalifa SAM; El-Seedi HR
    Foods; 2021 Jul; 10(8):. PubMed ID: 34441553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In silico screening of some compounds derived from the desert medicinal plant Rhazya stricta for the potential treatment of COVID-19.
    Baeshen NA; Albeshri AO; Baeshen NN; Attar R; Karkashan A; Abbas B; Bouback TA; Aljaddawi AA; Refai MY; Abdelkader HS; Al Tamim A; Alowaifeer A; Ahmed F; Baeshen MN
    Sci Rep; 2022 Jul; 12(1):11120. PubMed ID: 35778482
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The structural basis of accelerated host cell entry by SARS-CoV-2†.
    Seyran M; Takayama K; Uversky VN; Lundstrom K; Palù G; Sherchan SP; Attrish D; Rezaei N; Aljabali AAA; Ghosh S; Pizzol D; Chauhan G; Adadi P; Mohamed Abd El-Aziz T; Soares AG; Kandimalla R; Tambuwala M; Hassan SS; Azad GK; Pal Choudhury P; Baetas-da-Cruz W; Serrano-Aroca Á; Brufsky AM; Uhal BD
    FEBS J; 2021 Sep; 288(17):5010-5020. PubMed ID: 33264497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The study of antiviral drugs targeting SARS-CoV-2 nucleocapsid and spike proteins through large-scale compound repurposing.
    Hu X; Zhou Z; Li F; Xiao Y; Wang Z; Xu J; Dong F; Zheng H; Yu R
    Heliyon; 2021 Mar; 7(3):e06387. PubMed ID: 33688584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitory mechanism of Ambroxol and Bromhexine Hydrochlorides as potent blockers of molecular interaction between SARS-CoV-2 spike protein and human angiotensin-converting Enzyme-2.
    Kehinde IA; Egbejimi A; Kaur M; Onyenaka C; Adebusuyi T; Olaleye OA
    J Mol Graph Model; 2022 Jul; 114():108201. PubMed ID: 35487151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In silico investigations of heparin binding to SARS-CoV-2 variants with a focus at the RBD/ACE2 interface.
    Ali N; Khan R; AlAsmari AF; Kumar V
    Process Biochem; 2022 Apr; 115():70-79. PubMed ID: 35194375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of Kaempferol as Viral Entry Inhibitor and DL-Arginine as Viral Replication Inhibitor from Selected Plants of Indian Traditional Medicine against COVID-19: An
    Jayaprakashkamath A; Murali M; Nair B; Benny F; Mani RP; Suresh D; Presanna AT; Areekkara AN; Nath LR
    Curr Comput Aided Drug Des; 2023; 19(4):313-323. PubMed ID: 36635906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An
    Behera SK; Mahapatra N; Tripathy CS; Pati S
    Indian J Med Res; 2021 Jan & Feb; 153(1 & 2):132-143. PubMed ID: 33818470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urtica dioica Agglutinin: A plant protein candidate for inhibition of SARS-COV-2 receptor-binding domain for control of Covid19 Infection.
    Sabzian-Molaei F; Nasiri Khalili MA; Sabzian-Molaei M; Shahsavarani H; Fattah Pour A; Molaei Rad A; Hadi A
    PLoS One; 2022; 17(7):e0268156. PubMed ID: 35901082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tinocordiside from
    Balkrishna A; Pokhrel S; Varshney A
    Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2.
    Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
    J Infect Public Health; 2021 Feb; 14(2):227-237. PubMed ID: 33493919
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.